Chad Deal, M.D.
Angelo Licata, M.D.,Ph.D.
Bradford Richmond, M.D.
Abby Abelson, M.D., F.A.C.R.
Chad Deal, M.D.
Deal C. Can calcium and vitamin D supplementation adequately treat most patients with osteoporosis? Cleveland Clinic Journal of Medicine 67(10): 696-697, 2000.
Lufkin EG, Wong M, Deal CL. The Role of Selective Estrogen Receptor Modulators in the Prevention and Treatment of Osteoporosis. Rheumatic Disease Clinics of North America 27(1):163-185, 2001.
Deal CL. Using Bone Densitometry to Monitor Therapy in Treating Osteoporosis: Pros and Cons, Current Rheumatology Reports 3:240-244, 2001.
Srivastava M, Deal CL. Medical management and prevention of fragility fractures. Advances in Osteoporotic Fracture Management 1:34-40, 2001.
Shivastava M, Deal C. Osteoporosis in elderly: prevention and treatment. Clin Geriatr Med 18: 529-555; 2002.
Deal CL. The hip trial : Risedronate prevents hip fractures, but who should get therapy? Cleveland Clinic Journal of Medicine 69(12): 964-975, 2002.
Deal C. Bone Densitometry and Osteoporosis Management : Focus on Financial and Managerial Aspects. Practice View : American College of Rheumatology vol 1, No. 13, 2003.
Deal C. Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosis. Cleveland Clinic Journal of Medicine 70(7): 585-601, 2003.
Deal C. The use of intermittent human parathyroid hormone as a treatment for osteoporosis. Current Rheumatology Reports 6: 49-58, 2004.
Miller PD, Bilezikian JP, Deal C, et al. Clinical use of teriparatide in the real world: Initial insights. Endocrine Practice 10(2): 139-148, March/April 2004.
Srivastava M, Deal C. Osteoporosis and hip fractures. Current Geriatric Diagnosis and Treatment. Palmer R. ed. Lange Medical Books, 2004
Deal C. Glucocortocoids and fracture risk. Osteoporosis Today 4(2): 4, 2004
Return to Top
Angelo Licata, M.D.,Ph.D.
Watts NB, Harris ST, Genant HK, Wasnich RD, Miller, PD, Jackson RD, Licata AA, et al.: Effects cyclical etidronate with or without phosphate in treatment of postmenopausal osteoporosis: Results of multicenter trial. N Engl J Med 323:73-9, 1990.
Harris ST, Jackson RD. Watts NB, Genant HK, Washnich RD, Ross PD, Miller PD, Licata AA, Chesnut III CH: Effects of four years of intermittent cyclical etidronate treatment for postmenopausal osteoporosis. Amer J Med 95:557-67, 1993.
Lonzer MD, Imrie R, Rogers D, Worley D, Licata AA, Secic M. Effects of heredity, age, weight, puberty, activity and calcium intake on bone mineral density in children. Clin Pediat 35:185-189, 1996.
Miller PD, Watts NB, Licata AA, Harris ST, Genant HK, et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis:efficacy and safety after 7 years of treatment. American Journal Medicine 103(6):468-476, 1997.
Harris ST, Watts NE, Genant HK, et al. Effect of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis. JAMA (1999);282: 1344-1352.
Lindsay R, Silverman S, Cooper C, Hanley DA, Barton I, Licata AA, et al. Increased risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320-3.
Licata AA. Osteoporosis in men: secondary disease is a primary consideration and primary disease is a secondary consideration. Cleveland Clinic Journal Medicine 2003; 70: 501
Licata AA. Update on the diagnostic and treatment guidelines for osteoporosis. Cortlandt Forum 2003; 16:14- 29.
Licata AA. An updated look at therapies for osteoporosis. The Clinical Advisor 2003; 6(12):10-22.
Return to Top
Bradford Richmond, M.D.
Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ, Mysiw WJ, Kohse L, Rao MB, Steiger P, Richmond BJ, Chestnut C. Intermittent Cyclical Etidronate Treatment of Postmenapausal Osteoporosis. NEJM 1990; 323:73-79.
Schils JP, Piraino D, Richmond BJ, Stulb erg B, Belhobek GH, Licata A. Transient Osteoporosis of the Hip: Clinical and Imaging Features. Cleveland Clinic Journal of Medicine 1992;59(5):483-488
Lee AM, Skibinski C, Richmond BJ, Licata AA. Clinical-experience with cyclical etidronate in patients with osteoporosis. Journal of Bone and Mineral Research 1993 Vol 8 August 247
Braun WE, Richmond BJ. The incidence and management of osteoporosis, gout and avascular necrosis in recipients of renal allografts functioning more than 20 years (level 5A). Transplant Procedure 1999 Feb-Mar;31(1-2):1366-1369
Saadi H, Litaker D, Mills W, Kippes C, Richmond BJ, Licata A. Practice Variation in the Diagnosis and Treatment of Osteoporosis: A Case for More Effective Physician Education in Primary Care. Journal of Women's Health & Gender-Based Medicine 1999, 767-771
Richmond BJ. DXA: Do you know what the results mena? Cleveland Clinic Journal of Medicine 2003 April:70(4):353-360
Thacker, HL, Richmond, BJ, Does Bone Size Affect Bone Growth commentary, OBG Management, 2003: Vol. 15, (11):14-16.
Return to Top
Miriam Delaney, M.D., M.R.C.P.I., F.A.C.E.
Kifor O, Moore FD, Delaney M, Garber J, Hendy GN, Butters R, Gao P, Cantor T, Kifor I, Brown EM, Wysolmerski J. "Autoimmune" Familial Hypocaliuric Hypercalcemia (FHH) Caused by Blocking Autoantibodies to the Calcium-Sensing Receptor (CaR). J Clin Endocrinol Metab 2003;88:60-72.
Delaney MF, Hurwitz S, Shaw J, LeBoff MS. Bone density changes with once-weekly risedronate in postmenopausal women. J Clin Densitom 2003 Spring;6(1):45-50.
Return to Top
Abby Abelson, M.D., F.A.C.R.
publications not yet available
Return to Top
John Carey, M.D.
Carey J, Spence L, Blickman H, Eustace S. MRI of pediatric growth plate injury: correlation with plain film radiographs and clinical outcome. Skeletal Radiol. 1998 May;27(5): 250-5.
Eustace S, Tello R, DeCarvalho V, Carey J. Whole body turbo STIR MRI in unknown primary tumor detection. J Magn Reson Imaging. 1998 May-Jun; 8(3): 751-3.
Eustace S, Tello R, DeCarvalho V, Carey J. A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene disphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. AJR Am J Roentgenol. 1997 Dec;169(6): 1655-61.
Wadhwani A, Carey J, Propeck T. Isolated scaphotrapezoid osteoarthritis: a possible radiographic marker of chronic scapholunate ligament disruption. Clin Radiol. 1998 May; 53(5): 376-8.
Adams JG, McAlindon T, Dimasi M, Carey J, Eustace S. Contribution of meniscal extrusion and cartilage loss to joint space narrowing in osteoarthritis. Clin Radiol. 1999 Aug; 54(8):502-6.
Carey J. Wilke W. Osteoarthritis. Cleveland Clinic Disease Management Project 2004: www.clevelandclinicmeded.com.
Return to Top
September 3, 2004
